Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells

Yagi,Chihiro; Tatsuoka,Juri; Sano,Emiko; Hanashima,Yuya; Ozawa,Yoshinari; Yoshimura,Sodai; Yamamuro,Shun; Sumi,Koichiro; Hara,Hiroyuki; Katayama,Yoichi; Yoshino,Atsuo

doi:10.3892/or.2022.8431

Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells

Authors:
- Chihiro Yagi
- Juri Tatsuoka
- Emiko Sano
- Yuya Hanashima
- Yoshinari Ozawa
- Sodai Yoshimura
- Shun Yamamuro
- Koichiro Sumi
- Hiroyuki Hara
- Yoichi Katayama
- Atsuo Yoshino
View Affiliations

Affiliations: Department of Neurological Surgery, Nihon University School of Medicine, Tokyo 173‑8610, Japan, Department of Functional Morphology, Nihon University School of Medicine, Tokyo 173‑8610, Japan
Published online on: October 21, 2022 https://doi.org/10.3892/or.2022.8431
Article Number: 216
Copyright: © Yagi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with glioblastoma frequently suffer epileptic seizures and often require anticonvulsant therapy during the treatment course. The present study investigated four common antiepileptic drugs, perampanel, carbamazepine (CBZ), sodium valproate (VPA) and levetiracetam (LEV), which are expected to have antitumor effects, and determined the most beneficial drug for the treatment of malignant glioma by comparing antitumor effects such as inhibition of cell proliferation and suppression of migration and invasion (using Transwell assays). The inhibition of cell growth was investigated using six malignant glioma cell lines (A‑172, AM‑38, T98G, U‑138MG, U‑251MG and YH‑13). Significant inhibition of cell proliferation was observed in all six cell lines treated with perampanel, three cell lines treated with CBZ, four cell lines treated with VPA and two cell lines treated with LEV at the therapeutic blood concentration levels for the drugs to be used as antiepileptics. Further antitumor effects in combination with temozolomide were investigated using T98G and U‑251MG cell lines, and were confirmed in both cell lines with perampanel and in T98G cells with LEV, but not observed with CBZ and VPA. Cell migration was significantly suppressed in both T98G and U‑251MG cell lines with perampanel, but not with CBZ, VPA or LEV. To investigate the mechanisms by which perampanel suppresses the migration of malignant glioma cells, the expression of mRNA related to epithelial‑mesenchymal transition following perampanel treatment was analyzed using reverse transcription‑quantitative PCR in the T98G and U‑251MG cell lines. The expression of Rac1 and RhoA, which constitute the cytoskeleton that enhances cell motility, were reduced in both cell lines. Furthermore, the expression of the mesenchymal marker N‑cadherin, which promotes cell migration and infiltration, was decreased, but the expression of the epithelial marker E‑cadherin, which strengthens cell‑cell adhesion and reduces cell motility, was increased. Furthermore, the expression of matrix metalloproteinase‑2, a proteolytic enzyme, was reduced. These effects may reduce cell motility and increase adhesion between cells, suggesting that perampanel treatment suppressed cell migration. In conclusion, the present study suggests that perampanel may be more beneficial in terms of antitumor efficacy than other antiepileptic drugs for the treatment of malignant glioma.

View Figures

View References

1	No authors listed, . Brain tumor registry of Japan (2005–2008). Neurol Med Chir (Tokyo). 57 (Suppl 1):S9–S102. 2017. View Article : Google Scholar
2	Knudsen-Baas KM, Engeland A, Gilhus NE, Storstein AM and Owe JF: Does the choice of antiepileptic drug affect survival in glioblastoma patients? J Neurooncol. 129:461–469. 2016. View Article : Google Scholar : PubMed/NCBI
3	Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, et al: Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 77:1156–1164. 2011. View Article : Google Scholar : PubMed/NCBI
4	Barker CA, Bishop AJ, Chang M, Beal K and Chan TA: Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys. 86:504–509. 2013. View Article : Google Scholar : PubMed/NCBI
5	Jabbarli R, Ahmadipour Y, Rauschenbach L, Santos AN, Darkwah Oppong M, Pierscianek D, Quesada CM, Kebir S, Dammann P, Guberina N, et al: How about levetiracetam in glioblastoma? An institutional experience and meta-analysis. Cancers (Basel). 13:37702021. View Article : Google Scholar : PubMed/NCBI
6	Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, et al: Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol. 34:731–739. 2016. View Article : Google Scholar : PubMed/NCBI
7	French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D and Rogawski MA: Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304. Neurology. 79:589–596. 2012. View Article : Google Scholar : PubMed/NCBI
8	Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J and Fine HA: Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial. J Clin Oncol. 27:4155–4161. 2009. View Article : Google Scholar : PubMed/NCBI
9	Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS and Fine HA: Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer. 116:1776–1782. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lange F, Weßlau K, Porath K, Hörnschemeyer J, Bergner C, Krause BJ, Mullins CS, Linnebacher M, Köhling R and Kirschstein T: AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. PLoS One. 14:e02116442019. View Article : Google Scholar : PubMed/NCBI
11	Salmaggi A, Corno C, Maschio M, Donzelli S, D'Urso A, Perego P and Ciusani E: Synergistic effect of perampanel and temozolomide in human glioma cell lines. J Pers Med. 11:3902021. View Article : Google Scholar : PubMed/NCBI
12	Izumoto S, Miyauchi M, Tasaki T, Okuda T, Nakagawa N, Nakano N, Kato A and Fujita M: Seizures and tumor progression in glioma patients with uncontrollable epilepsy treated with perampanel. Anticancer Res. 38:4361–4366. 2018. View Article : Google Scholar : PubMed/NCBI
13	Tatsuoka J, Sano E, Hanashima Y, Yagi C, Yamamuro S, Sumi K, Hara H, Takada K, Kanemaru K, Komine-Aizawa S, et al: Anti-tumor effects of perampanel in malignant glioma cells. Oncol Lett. 24:4212022. View Article : Google Scholar
14	Lefranc F, Le Rhun E, Kiss R and Weller M: Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets? Cancer Treat Rev. 68:145–154. 2018. View Article : Google Scholar : PubMed/NCBI
15	Corsi L, Mescola A and Alessandrini A: Glutamate receptors and glioblastoma multiforme: An old ‘route’ for new perspectives. Int J Mol Sci. 20:17962019. View Article : Google Scholar : PubMed/NCBI
16	Vollmann-Zwerenz A, Leidgens V, Feliciello G, Klein CA and Hau P: Tumor cell invasion in glioblastoma. Int J Mol Sci. 21:19322020. View Article : Google Scholar : PubMed/NCBI
17	Piao Y, Lu L and de Groot J: AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol. 11:260–273. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zhong J, Paul A, Kellie SJ and O'Neill GM: Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol. 2010:4301422010. View Article : Google Scholar : PubMed/NCBI
19	Catalano M, D'Alessandro G, Lepore F, Corazzari M, Caldarola S, Valacca C, Faienza F, Esposito V, Limatola C, Cecconi F and Di Bartolomeo S: Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells. Mol Oncol. 9:1612–1625. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhu X, Hu B, Hu M, Qian D and Wang B: Human cytomegalovirus infection enhances invasiveness and migration of glioblastoma cells by epithelial-to-mesenchymal transition. Int J Clin Exp Pathol. 13:2637–2647. 2020.PubMed/NCBI
21	Cuddapah VA, Robel S, Watkins S and Sontheimer H: A neurocentric perspective on glioma invasion. Nat Rev Neurosci. 15:455–465. 2014. View Article : Google Scholar : PubMed/NCBI
22	Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E and Tsumoto K: Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol. 36:1367–1377. 2010. View Article : Google Scholar : PubMed/NCBI
23	Wischhusen J, Naumann U, Ohgaki H, Rastinejad F and Weller M: CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene. 22:8233–8245. 2003. View Article : Google Scholar : PubMed/NCBI
24	Japanese Society of Neurology, . CQ12-2: Serum concentration monitoring is useful for which drugs? Clinical practice guidelines for epilepsy 2018. Igaku-Shoin Ltd; Tokyo: pp. 103–105. 2018, Available at:. https://neurology-jp.org/guidelinem/epilepsy/documents/guideline2018.pdfpp. 123–125. https://www.neurology-jp.org/guidelinem/tenkan_2018.htmlin Japanese.
25	Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 10:3728–3736. 2004. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Brodie MJ, Covanis A, Gil-Nagel A, Lerche H, Perucca E, Sills GJ and White HS: Antiepileptic drug therapy: Does mechanism of action matter? Epilepsy Behav. 21:331–341. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zhang C, Liu S, Yuan X, Hu Z, Li H, Wu M, Yuan J, Zhao Z, Su J, Wang X, et al: Valproic acid promotes human glioma U87 cells apoptosis and inhibits glycogen synthase kinase-3β through ERK/Akt signaling. Cell Physiol Biochem. 39:2173–2185. 2016. View Article : Google Scholar : PubMed/NCBI
29	Han W and Guan W: Valproic acid: A promising therapeutic agent in glioma treatment. Front Oncol. 11:6873622021. View Article : Google Scholar : PubMed/NCBI
30	Bello MJ, Alonso ME, Amiñoso C, Anselmo NP, Arjona D, Gonzalez-Gomez P, Lopez-Marin I, de Campos JM, Gutierrez M, Isla A, et al: Hypermethylation of the DNA repair gene MGMT: Association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res. 554:23–32. 2004. View Article : Google Scholar : PubMed/NCBI
31	Scicchitano BM, Sorrentino S, Proietti G, Lama G, Dobrowolny G, Catizone A, Binda E, Larocca LM and Sica G: Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int. 18:1362018. View Article : Google Scholar : PubMed/NCBI
32	de Bruin ME, van der Meer PB, Dirven L, Taphoorn MJB and Koekkoek JAF: Efficacy of antiepileptic drugs in glioma patients with epilepsy: A systematic review. Neurooncol Pract. 8:501–517. 2021.PubMed/NCBI
33	Galvao J, Davis B, Tilley M, Normando E, Duchen MR and Cordeiro MF: Unexpected low-dose toxicity of the universal solvent DMSO. FASEB J. 28:1317–1330. 2014. View Article : Google Scholar : PubMed/NCBI